Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|NRG-GI003||NRG||Phase III Randomized Trial of Protons versus Photons for Hepatocellular Carcinoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|9903||ETCTN||A Phase 1B Study of AZD9291 in Combination with Navitoclax in EGFR-mutant Non-Small Cell Lung Cancer Following Resistance to Initial EGFR Kinase Inhibitor||Adult CIRB - Early Phase Emphasis||Available to Open|
|A041702||Alliance||A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib plus Venetoclax and Obinutuzumab in Untreated Older Patients (= 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)||Adult CIRB - Late Phase Emphasis||Available to Open|
|PACCT-1||ECOG||Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial||Adult CIRB - Late Phase Emphasis||Available to Open|
|AAML0531||COG||A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined with Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children; Adolescents; and Young Adults||Pediatric CIRB||Available to Open|
|AHEP1531||COG||Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)||Pediatric CIRB||Available to Open|
|SCUSF-0901||COG||SCUSF 0901 [ACCL0922] A Phase II Placebo-Controlled Trial of Modafinil to Improve Neurocognitive Deficits in Children Treated for a Primary Brain Tumor||Pediatric CIRB||Available to Open|
|NRG-GI004||NRG||Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|WF-97415||NCORP-Wake Forest University||Understanding and Predicting Breast Cancer Events after Treatment (UPBEAT)||Cancer Prevention and Control CIRB||Available to Open|
|10250||ETCTN||A Phase II Study of the PARP Inhibitor Olaparib in Combination with the DNA Damaging Agent Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma||Adult CIRB - Early Phase Emphasis||Available to Open|